RCKT ▲ +4.1% - Rocket Pharmaceuticals, Inc. $RCKT - Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals rose 4.1% today following an announcement that the FDA has aligned with the company's plan to complete its pivotal Phase 2 trial of RP-A501 for Danon disease. The regulatory alignment on the trial pathway reduced uncertainty around one of the company's key clinical programs and provided visibility into next steps for the program. 15-SEP-2026 07:05 AM ET